CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Mississauga - Chow, Canada

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

    Phase

    3

    Span

    501 weeks

    Sponsor

    Regeneron Pharmaceuticals

    Las Condes

    Recruiting

  • A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

    Litifilimab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting blood dendritic cell antigen 2 and is being investigated for the potential treatment of systemic lupus erythematosus and cutaneous lupus erythematosus. The primary objectives of the study are to evaluate the efficacy of litifilimab compared with placebo in reducing skin disease activity measured by the CLA-IGA-R score [Parts A and B (US)] and the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score [Part B (ROW)] in participants with active SCLE and/or CCLE with or without systemic manifestations and refractory and/or intolerant to antimalarials. The secondary objectives of the study are to evaluate the efficacy of litifilimab in reducing SCLE and/or CCLE disease activity by CLA-IGA-R, CLASI-A; to evaluate additional efficacy parameters of litifilimab in reducing SCLE and/or CCLE disease activity; safety; tolerability; and immunogenicity of litifilimab [Parts A and B].

    Phase

    2/3

    Span

    274 weeks

    Sponsor

    Biogen

    Las Condes

    Recruiting

  • Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

    Phase

    3

    Span

    299 weeks

    Sponsor

    Gilead Sciences

    Las Condes

    Recruiting

  • A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

    Phase

    3

    Span

    445 weeks

    Sponsor

    AstraZeneca

    Las Condes

    Recruiting

  • A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

    Phase

    3

    Span

    199 weeks

    Sponsor

    Janssen Research & Development, LLC

    Las Condes

    Recruiting

  • A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

    Phase

    3

    Span

    269 weeks

    Sponsor

    Akero Therapeutics, Inc

    Las Condes, Región Metropolitana

    Recruiting

  • A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

    Phase

    2

    Span

    146 weeks

    Sponsor

    Sanofi

    Las Condes

    Recruiting

  • A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

    Phase

    3

    Span

    300 weeks

    Sponsor

    Ipsen

    Las Condes

    Recruiting

  • Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    Phase

    3

    Span

    217 weeks

    Sponsor

    Karuna Therapeutics

    Las Condes

    Recruiting

  • A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

    Phase

    3

    Span

    278 weeks

    Sponsor

    Regeneron Pharmaceuticals

    Las Condes

    Recruiting

1-10 of 13
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information